VA
TARA icon

Verdad Advisers’s Protara Therapeutics TARA Stock Holding History

Verdad Advisers’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.19M Buy
+312,249
New +$1.49M 1.14% 19

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Verdad Advisers's TARA Position: Q2 2026 in Review

Verdad Advisers opened a new position in Protara Therapeutics (TARA) in Q2 2026: 312,249 shares worth $1.19M. The stake represents 1.14% of the portfolio and ranks #19 among its holdings.

120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Verdad Advisers held 312,249 shares of Protara Therapeutics worth $1.19M as of Q2 2026.
  • Protara Therapeutics was a new Verdad Advisers position in Q2 2026.
  • Protara Therapeutics made up 1.14% of Verdad Advisers's portfolio in Q2 2026, its #19 holding.
  • 120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.